In APP AD models, for instance, the administration of cannabinoids [159] or PTP1B inhibitor trodusquemine [160] led to GSK3β-Ser9 re-phosphorylation together with improved memory and reduced inflammation (TNF mRNA and COX-2 protein levels [159], microglia activation [159,160]), Aβ levels [159], and neurodegeneration [160]. The gene discussed is APP; the disease is Alzheimer disease.